WEST LAFAYETTE, Ind., July 28, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host
a conference call on Thursday, August 4th, at 4:30 p.m. EDT to discuss its second quarter financial results and provide an
operational update.
Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors &
News section of the Company’s website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081
(International).
The webcast will be recorded and available on the Company’s website for 90 days following the call.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other
serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging
agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased
cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active
drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug
alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy
and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at
www.endocyte.com.
Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com
